Mar 10, 2019 - Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Shanghai RAAS, one of China's largest blood plasma companies, for $1.9 billion in a non-cash deal.Ambrx, a San Diego bioph
Mar 07, 2019 - Fortune's annual survey of the 100 best companies to work for turned up 46 publicly owned entities. Here's another list to test our dog metrics.Top net-gainers CMCSA, GS, CPT, T, ABBV, COF, FDX, EHC,
Mar 07, 2019 - Xeris Pharmaceuticals is awaiting FDA approval for their shelf-stable Gvoke HypoPen for the emergency treatment of acute hypoglycemia.The company's FDA PDUFA date is on June 10th and I want to start a
Mar 05, 2019 - The main drivers of value creation over time are growth and return on invested capital (in relation to cost of capital).The investing world has created investment styles such as growth and value, but
Mar 04, 2019 - Aeterna (AEZS) growth hormone deficiency test, Macrilen, to drive revenues in the fourth quarter.
Feb 27, 2019 - Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.
Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Feb 20, 2019 - Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Feb 13, 2019 - Novo Nordisk reported full year results for 2018, and while revenue was still stagnant, earning per share could grow 4%.Due to the launch of new products like Saxenda, Ozempic, and Oral Semaglutide, N
Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.